Article Text
Abstract
Introduction/Background Gemcitabine or liposomal doxorubicin are well-accepted chemotherapy modilities in management of recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response. In this study we aimed to evaluate the progression free intervals after the secondline gemcitabine or liposomal doxorubicin treatments in this group.
Methodology This is a descriptive retrospective study including 67 patients with recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response. Partial response was defined as recurrence after 6 first-line therapies with platine derives in 6–12months. Patients who underwent gemcitabine + platine derives ± bevacizumab was defined as Group I and liposomal doxorubicin + platine derives ± bevacizumab as Group II.
Results The median recurrence time of the whole group was 8 months. The mean initial recurrence times were 7.4±2.6 and 8.5±2.3 months for group I and II, respectively. The mean progression free survival time after in Group I and II were 13.6±6.1 and 13.7±19.7 months, (p:0.344), respectively. The estimated overall survival for groups were 59.0±7.2 months and 45.7±3.5 months but this was not statistically significant (p:0.135).
Conclusion In our study, we found that progression free intervals after the secondline gemcitabine or liposomal doxorubicin treatments in patients recurrent high grade serous ovarian cancer (HG-SOC) with partial platinum response are similar. This finding may support use of liposomal doxorubicin with longer treatment intervals and less hospital admission for the patient.
Disclosures none